ArticleInternational journal of hypertension2011
Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome.
Article in International journal of hypertension, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 55 citations in OpenAlex.
- Vasodilator responses and endothelin-dependent vasoconstriction in metabolically healthy obesity and the metabolic syndrome.American journal of physiology. Endocrinology and metabolism · 2015Trial
- Time to Change Our Viewpoints to Assess Renal Risks in Patients with Solitary Kidneys beyond Traditional Approaches?Journal of clinical medicine · 2023Article
- Review
- Understanding diabetes-induced cardiomyopathy from the perspective of renin angiotensin aldosterone system.Pflugers Archiv : European journal of physiology · 2022Review
- Homocysteine predicts vascular target organ damage in hypertension and may serve as guidance for first-line antihypertensive therapy.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
- Association of hypertension and incident diabetes in Chinese adults: a retrospective cohort study using propensity-score matching.BMC endocrine disorders · 2021Article
- Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use prior to medical intensive care unit admission and in-hospital mortality: propensity score-matched cohort study.Journal of nephrology · 2019Article
- Measurement of the total angiotensinogen and its reduced and oxidised forms in human plasma using targeted LC-MS/MS.Analytical and bioanalytical chemistry · 2019Article
- Ablation of TRPV1 Elevates Nocturnal Blood Pressure in Western Diet-fed Mice.Current hypertension reviews · 2019Article
- Glycated hemoglobin correlates with arterial stiffness and endothelial dysfunction in patients with resistant hypertension and uncontrolled diabetes mellitus.Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
- Independent Association of Serum Aldosterone Level with Metabolic Syndrome and Insulin Resistance in Korean Adults.Korean circulation journal · 2018Article
- Cardiac Development and Transcription Factors: Insulin Signalling, Insulin Resistance, and Intrauterine Nutritional Programming of Cardiovascular Disease.Journal of nutrition and metabolism · 2018Review
- Beneficial Effects of Bariatric Surgery on Cardiac Structure and Function in Obesity.Obesity surgery · 2017Article
- Prenatal exposure to lipopolysaccharide results in local RAS activation in the adipose tissue of rat offspring.PloS one · 2014Article
- Article
- Article
- Relationships of hardiness to physical and mental health status in military men: a test of mediated effects.Journal of behavioral medicine · 2013Article
- Effects of blocking of angiotensin system on the prevalence of metabolic syndrome in type 2 diabetic patients.Pakistan journal of medical sciences · 2013Article
- RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes.Journal of diabetes research · 2013Article
- Over-nutrition and metabolic cardiomyopathy.Metabolism: clinical and experimental · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aldosterone facilitates cardiovascular damage by increasing blood pressure and through different mechanisms that are independent of its effects on blood pressure. In this respect, recent evidence involves aldosterone in the pathogenesis of metabolic syndrome. Although this relationship is complex, there is some evidence suggesting that different factors may play an important role, such as insulin resistance, renin-angiotensin-aldosterone system, oxidative stress, sodium retention, increased sympathetic activity, levels of free fatty acids, or inflammatory cytokines and adipokines. In addition to the classical pathway by which aldosterone acts through the mineralocorticoid receptors leading to sodium retention, aldosterone also has other mechanisms that influence cardiovascular tissue remodelling. Finally, overweight and obesity promote the adrenal secretion of aldosterone, increasing the predisposition to type 2 diabetes mellitus. Further studies are needed to better establish therapeutic strategies that act on the blockade of mineralocorticoid receptor in the treatment and prevention of cardiovascular diseases related to the excess of aldosterone and the metabolic syndrome.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.